Sarepta Therapeutics, Inc. SRPT 深 沪
已收盘 10-23 16:00:00 美东时间
17.73
-0.450
-2.48%
华盛通- 最 高18.12
- 今 开17.94
- 成交量 128.55万股
- 最 低 17.155
- 昨 收 18.18
- 总市值 18.73亿
- 52周最高 24.68
- 市盈率 静 --
- 换手率 1.22%
- 52周最低 14.68
- 委 比 -32.80%
- 总股本 1.06亿
- 历史最高 181.83
- 量 比 0.34
- 振 幅 5.31%
- 历史最低 0.433
- 每 手 1
- 风险率 2.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Sarepta Therapeutics收跌3.88%，成交额1.69亿美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 05:31
美股大行评级 | 潜在涨幅179.23%！奥本海默上调Aurora Innovation目标价至16美元，维持"跑赢大市"评级
今日重点评级关注：奥本海默：维持Aurora Innovation"跑赢大市"评级，目标价从15美元升至16美元；富国银行：维持Applied Digital"超配"评级，目标价从50美元升至55美元
10-09 16:25
Jim Cramer: This Tech Stock Is 'Very Good,' Avery Dennison Is A ‘Winner’
On CNBC’s “Mad Money Lightning Round,” Jim Cramer said Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a “very controversial” stock. HC Wainwright & Co. analyst Mitchell S. Kapoor reiterated a Sell rating on Sarepta Therapeutics on Monday and maintained a $5 price target. Avery Dennison Corporation (NYS...
10-06 20:17
美股大行评级 | 瑞银维持康宁“买入”评级，上调目标价至201美元；大摩维持泛林集团“超配”评级
今日重点评级关注：Needham：维持iRhythm Holdings"买入"评级，目标价从192美元升至194美元；HC Wainwright & Co.：维持5E Advanced Materials"买入"评级，目标价从3.5美元升至6.75美元
10-06 16:45
HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and maintains $5 price target.
10-05 19:54
美股大行评级 | 潜在涨幅600.93%！Ascendiant Capital上调Aytu BioPharma目标价至15美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从14.5美元升至15美元；摩根大通：维持Annexon"超配"评级，目标价从14美元升至15美元
10-01 19:18
Needham Reiterates Underperform on Sarepta Therapeuticsto Underperform
Needham analyst Gil Blum reiterates Sarepta Therapeutics (NASDAQ:SRPT) from Underperform to Underperform.
09-28 18:14
Sarepta Resolves AAVrh74 Gene Therapy Patent Dispute
Sarepta Therapeutics ( ($SRPT) ) has provided an announcement. On September 23,...
09-24 04:28
REGENXBIO Says All Ongoing Patent Litigation Regarding Patents-In-Suit To Be Terminated With Prejudice; Agrees Not To Sue Sarepta Or Affiliates Over Existing Elevidys Or AAVrh74-Based Capsids
On September 23, 2026, REGENXBIO Inc. (the "Company") and The Trustees of the University of Pennsylvania ("UPenn") entered into a Settlement Agreement (the "Settlement Agreement") with Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three, LLC (together with Sarepta Therapeutics, Inc., "Sarepta"...
09-24 04:21
FDA, Duke-Margolis workshop to examine evidence standards for rare diseases
The Food and Drug Administration and Duke-Margolis Institute for Health Policy will convene a public workshop this month to examine one of the most difficult questions in rare disease development: how...
09-21 02:57
